1
|
Ding D, Zhang Y, Zhang X, Shi K, Shang W, Ying J, Wang L, Chen Z, Hong H. MiR-30a-3p Suppresses the Growth and Development of Lung Adenocarcinoma Cells Through Modulating GOLM1/JAK-STAT Signaling. Mol Biotechnol 2022; 64:1143-1151. [PMID: 35438415 DOI: 10.1007/s12033-022-00497-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2022] [Accepted: 04/11/2022] [Indexed: 11/27/2022]
Abstract
A considerable amount of people succumbs to lung adenocarcinoma (LUAD) due to its high incidence and mortality. This study attempted to reveal the impacts of GOLM1 on LUAD. This work analyzed GOLM1 expression in LUAD and normal tissue and studied its prognostic value utilizing data from The Cancer Genome Atlas. RNA and protein levels were, respectively, determined utilizing qRT-PCR and western blot. Cell-aggressive behaviors were assessed employing Cell Counting Kit-8, scratch healing, and Transwell assays. The targetting relationship between GOLM1 and miR-30a-3p was assayed by dual-luciferase method. GOLM1 up-regulation in LUAD was found in TCGA and it was also a negative factor for survival in patients. GOLM1 overexpression promoted cell progression in LUAD. Down-regulated miR-30a-3p in LUAD was an upstream regulatory miRNA of GOLM1 in terms of molecular mechanism. Further, rescue assays illustrated that miR-30a-3p overexpression attenuated the GOLM1 facilitating impacts on LUAD progression. Finally, we proved that miR-30a-3p/GOLM1 regulated progression of LUAD cells via JAK-STAT pathway. Collectively, the inhibitory impacts of miR-30a-3p on LUAD growth may be mediated by GOLM1/JAK-STAT, which may contribute to the diagnosis of LUAD therapy and the development of therapeutic tools.
Collapse
Affiliation(s)
- Dongxiao Ding
- Department of Thoracic Surgery, The People's Hospital of Beilun District (Beilun Branch of the First Affiliated Hospital of Medical College of Zhejiang University), No.1288, East Lushan Road, Xinqi Sub-District, Beilun District, Zhejiang Province, Ningbo City, 315800, China
| | - Yunqiang Zhang
- Department of Thoracic Surgery, The People's Hospital of Beilun District (Beilun Branch of the First Affiliated Hospital of Medical College of Zhejiang University), No.1288, East Lushan Road, Xinqi Sub-District, Beilun District, Zhejiang Province, Ningbo City, 315800, China
| | - Xuede Zhang
- Department of Thoracic Surgery, The People's Hospital of Beilun District (Beilun Branch of the First Affiliated Hospital of Medical College of Zhejiang University), No.1288, East Lushan Road, Xinqi Sub-District, Beilun District, Zhejiang Province, Ningbo City, 315800, China
| | - Ke Shi
- Department of Thoracic Surgery, The People's Hospital of Beilun District (Beilun Branch of the First Affiliated Hospital of Medical College of Zhejiang University), No.1288, East Lushan Road, Xinqi Sub-District, Beilun District, Zhejiang Province, Ningbo City, 315800, China
| | - Wenjun Shang
- Department of Thoracic Surgery, The People's Hospital of Beilun District (Beilun Branch of the First Affiliated Hospital of Medical College of Zhejiang University), No.1288, East Lushan Road, Xinqi Sub-District, Beilun District, Zhejiang Province, Ningbo City, 315800, China
| | - Junjie Ying
- Department of Thoracic Surgery, The People's Hospital of Beilun District (Beilun Branch of the First Affiliated Hospital of Medical College of Zhejiang University), No.1288, East Lushan Road, Xinqi Sub-District, Beilun District, Zhejiang Province, Ningbo City, 315800, China
| | - Li Wang
- Department of Thoracic Surgery, The People's Hospital of Beilun District (Beilun Branch of the First Affiliated Hospital of Medical College of Zhejiang University), No.1288, East Lushan Road, Xinqi Sub-District, Beilun District, Zhejiang Province, Ningbo City, 315800, China
| | - Zhongjie Chen
- Department of Thoracic Surgery, The People's Hospital of Beilun District (Beilun Branch of the First Affiliated Hospital of Medical College of Zhejiang University), No.1288, East Lushan Road, Xinqi Sub-District, Beilun District, Zhejiang Province, Ningbo City, 315800, China
| | - Haihua Hong
- Department of Thoracic Surgery, The People's Hospital of Beilun District (Beilun Branch of the First Affiliated Hospital of Medical College of Zhejiang University), No.1288, East Lushan Road, Xinqi Sub-District, Beilun District, Zhejiang Province, Ningbo City, 315800, China.
| |
Collapse
|
2
|
Martins M, Fernandes AS, Saraiva N. GOLGI: Cancer cell fate control. Int J Biochem Cell Biol 2022; 145:106174. [PMID: 35182766 DOI: 10.1016/j.biocel.2022.106174] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Revised: 02/11/2022] [Accepted: 02/12/2022] [Indexed: 11/16/2022]
Abstract
Growing evidence connects many of the Golgi known functions with cellular events related to cancer initiation and progression, including regulation of cell survival/death, proliferation, motility, metabolism and immune evasion. However, a broad and integrated understanding of the impact of the Golgi on cancer cell phenotype has not yet been achieved. Multiple cellular events involving the Golgi are associated with protein and lipid modification and trafficking. However, less explored aspects of this enigmatic organelle also contribute to cell fate decision-making by impacting signal transduction, redox and ion homeostasis. This article focuses on the molecular mechanisms and Golgi proteins underlying the impact of the Golgi on cancer cell phenotype. Special emphasis is given to emerging knowledge on redox and ion homeostasis. Current and potential cancer progression therapeutic strategies associated with this organelle will also be addressed.
Collapse
Affiliation(s)
- Marta Martins
- CBIOS - Universidade Lusófona's Research Center for Biosciences & Health Technologies, Campo Grande 376, 1749-024 Lisboa, Portugal
| | - Ana Sofia Fernandes
- CBIOS - Universidade Lusófona's Research Center for Biosciences & Health Technologies, Campo Grande 376, 1749-024 Lisboa, Portugal
| | - Nuno Saraiva
- CBIOS - Universidade Lusófona's Research Center for Biosciences & Health Technologies, Campo Grande 376, 1749-024 Lisboa, Portugal.
| |
Collapse
|
3
|
Suppression of GOLM1 by EGCG through HGF/HGFR/AKT/GSK-3β/β-catenin/c-Myc signaling pathway inhibits cell migration of MDA-MB-231. Food Chem Toxicol 2021; 157:112574. [PMID: 34536514 DOI: 10.1016/j.fct.2021.112574] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Revised: 09/03/2021] [Accepted: 09/14/2021] [Indexed: 02/03/2023]
Abstract
Golgi Membrane Protein 1 (GOLM1) has been identified as a prime target for cancer therapy because it overexpresses in many solid tumors, increases tumor growth and metastasis and leads to unfavorable survival. Though various approaches including siRNA interference and antibody targeting have been attempted, GOLM1 has remained an un-targetable molecule because of its mainly intracellular location and the lack of domains that could possibly be interfered with by small molecules. Numerous natural anti-tumoral plant substances have been identified, while their possible function on GOLM1 has never been revealed. This is the first report to study the relationship between GOLM1 downregulation and natural anti-tumoral plant substances and the possible mechanism. Among three tested possible migration-inhibiting natural substances (Epigallocatechin gallate (EGCG), Betulinic acid (BA) and Lupeol), EGCG showed the most potent inhibition effect on GOLM1 expression and MDA-MB-231 cell migration. Knocking down GOLM1 expression further increased the EGCG treatment effect. Molecular docking prediction and following experiments suggested that EGCG may inhibit GOLM1 expression and MDA-MB-231 cells migration through HGF/HGFR/AKT/GSK-3/β-catenin/c-Myc signaling pathway. In all, EGCG is the first identified GOLM1 downregulation natural product. Silencing GOLM1 may be a novel mechanism of potentiated anti-cancer migration effects and cytotoxic effect of EGCG. In addition, this study shed a new way for cancer therapy by combination of GOLM1 silencing and EGCG treatment in the future.
Collapse
|
4
|
Zhang Y, Qiu N, Zhang Y, Yan H, Ji J, Xi Y, Yang X, Zhao X, Zhai G. Oxygen-carrying nanoparticle-based chemo-sonodynamic therapy for tumor suppression and autoimmunity activation. Biomater Sci 2021; 9:3989-4004. [PMID: 33908449 DOI: 10.1039/d1bm00198a] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Sonodynamic therapy (SDT) is a promising non-invasive approach for cancer therapy. However, tumor hypoxia, a pathological characteristic of most solid tumor types, poses a major challenge in the application of SDT. In this study, a novel CD44 receptor-targeted and redox/ultrasound-responsive oxygen-carrying nanoplatform was constructed using chondroitin sulfate (CS), reactive oxygen species (ROS)-generating sonosensitizer Rhein (Rh), and perfluorocarbon (PFC). Perfluoroalkyl groups introduced into the structures preserved the oxygen carrying ability of PFC, increasing the oxygen content in B16F10 melanoma cells and enhancing the efficiency of SDT. Controlled nanoparticles without PFC generated lower ROS levels and exerted inferior tumor inhibition effects, both in vitro and in vivo, under ultrasound-treatment. In addition, SDT promoted immunogenic cell death (ICD) by inducing exposure of calreticulin (CRT) after treatment with CS-Rh-PFC nanoparticles (NPs). The immune system was significantly activated by docetaxel (DTX)-loaded NPs after SDT treatment due to the enhanced secretion of IFN-γ, TNF-α, IL-2 and IL-6 cytokines and tumor-infiltrating CD4+ and CD8+ T cell contents. Our findings support the utility of CS-Rh-PFC as an effective anti-tumor nanoplatform that promotes general immunity and accommodates multiple hydrophobic drugs to enhance the beneficial effects of chemo-SDT therapy.
Collapse
Affiliation(s)
- Yanan Zhang
- Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, PR China.
| | - Na Qiu
- Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, PR China.
| | - Yu Zhang
- Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, PR China.
| | - Huixian Yan
- Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, PR China.
| | - Jianbo Ji
- Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, PR China.
| | - Yanwei Xi
- Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, PR China.
| | - Xiaoye Yang
- Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, PR China.
| | - Xiaogang Zhao
- Department of Thoracic Surgery, The Second Hospital of Shandong University, Jinan, Shandong 250033, China.
| | - Guangxi Zhai
- Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, PR China.
| |
Collapse
|